Related content

Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor α in primary central nervous system lymphoma

By Karabatsou K.   Pal P.   Dodd S.   Haylock B.   Aguirreburualde M.   Moxam N.   Pinson-Ellis W.   Broome J.   Rainov N.G.  

Journal of Neuro-Oncology, Vol. 79, Iss. 2, 2006-09 ,pp. : 171-179

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration

By Dittrich C.   Greim G.   Borner M.   Weigang-Kohler K.   Huisman H.   Amelsberg A.   Ehret A.   Wanders J.   Hanauske A.   Fumoleau P.   for the EORTC Early Clinical Studies Group ECSG  

European Journal of Cancer, Vol. 38, Iss. 8, 2002-05 ,pp. : 1072-1080

Elsevier

Access to resources Recommend Favorite

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

By Chiorean E.   Sweeney Christopher   Youssoufian Hagop   Qin Amy   Dontabhaktuni Aruna   Loizos Nick   Nippgen Johannes   Amato Robert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 595-604

Springer Publishing Company

Access to resources Recommend Favorite

The Effects of Platelet-Derived Growth Factor and Receptor on Normal and Neoplastic Human Ovarian Surface Epithelium

By Dabrow M.B.   Francesco M.R.   McBrearty F.X.   Caradonna S.  

Gynecologic Oncology, Vol. 71, Iss. 1, 1998-10 ,pp. : 29-37

Elsevier

Access to resources Recommend Favorite

Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas

By Morris Patrick  

Targeted Oncology, Vol. 5, Iss. 3, 2010-09 ,pp. : 193-200

Springer Publishing Company

Access to resources Recommend Favorite